GLPG-0259 clinical trials
Also written GLPG0259.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses GLPG-0259 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GLPG0259
- 3
Studies by the year they started
5 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2009 | 3 |
| 2010 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses GLPG-0259 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- First-in-Human Single Ascending and Multiple Dose of GLPG0259CompletedPhase 1Galapagos NVNCT00905138Written as GLPG0259
- GLPG0259 Multiple Ascending Dose and Methotrexate Drug-drug Interaction (DDI) in Healthy SubjectsCompletedPhase 1Galapagos NVNCT00989703Written as GLPG0259
- GLPG0259 in Methotrexate-refractory Rheumatoid ArthritisCompletedPhase 2Galapagos NVNCT01211249Written as GLPG0259 oral capsule
- Oral Bioavailability of Two Solid Formulations of GLPG0259.CompletedPhase 1Lakefront Biotherapeutics NVNCT01322451Written as GLPG0259 fumarate
- GLPG0259 Solid Formulation Bioavailability and Food EffectCompletedPhase 1Galapagos NVNCT01024517Written as GLPG0259 solution